-
Stifel Reiterates Hold Rating on Senseonics Holdings (SENS)
-
Senseonics gets European approval for year-long glucose monitor
-
Senseonics reports Q4 revenue of $14.2 million, up 71% year-over-year
-
Senseonics launches first commercial pairing of Eversense 365 with AID system
-
TD Cowen on Senseonics Holdings (SENS): '2026 Setup Is Attractive'
-
Senseonics acquires Eversense distribution rights from Ascensia
-
Senseonics to transfer stock listing from NYSE American to NASDAQ
-
Senseonics Holdings (SENS) Misses Q3 EPS by 41c
-
Stifel Resumes Senseonics Holdings (SENS) at Hold
-
H.C. Wainwright Reiterates Buy Rating on Senseonics Holdings (SENS)
-
Mizuho on Senseonics Holdings (SENS): 'we see the pending separation as a positive turning point'
-
Senseonics to take over Eversense 365 commercialization from Ascensia
-
Barclays Starts Senseonics Holdings (SENS) at Overweight
-
Raymond James Reiterates Underperform Rating on Senseonics Holdings (SENS)
-
Senseonics Holdings (SENS) Reports In-Line Q2 EPS ; Offers Guidance
-
Lake Street Capital Markets Starts Senseonics Holdings (SENS) at Buy
-
TD Cowen Starts Senseonics Holdings (SENS) at Buy
-
Senseonics Holdings (SENS) PT Raised to $1.40 at H.C. Wainwright
-
H.C. Wainwright Assumes Senseonics Holdings (SENS) at Buy
-
Senseonics Holdings (SENS) Announces Pricing of $50M Public Offering of Common Stock and Concurrent Private Placement
-
Senseonics Holdings (SENS) Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
-
Senseonics Holdings (SENS) Tops Q1 EPS by 1c
-
Mizuho Starts Senseonics Holdings (SENS) at Outperform
-
H.C. Wainwright Reiterates Buy Rating on Senseonics Holdings (SENS)
-
Raymond James Reiterates Underperform Rating on Senseonics Holdings (SENS)
-
Stifel Reiterates Buy Rating on Senseonics Holdings (SENS)
-
Senseonics Holdings (SENS) Tops Q4 EPS by 1c
-
Senseonics Holdings (SENS) Files for 45.71M Share Offering
-
Senseonics Holdings (SENS) Misses Q3 EPS by 1c
-
Senseonics Holdings (SENS) Announces 45.71M Share Offering at $0.35/sh
-
Senseonics Holdings (SENS) announced that the first commercial patient received the next-generation Eversense 365 CGM system
-
BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
-
Stifel Reiterates Buy Rating on Senseonics Holdings (SENS)
-
Senseonics: Eversense 365 Receives FDA Clearance
-
Senseonics Holdings (SENS) Reports In-Line Q2 EPS, provides guidance
-
BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
-
Senseonics Holdings (SENS) Issues FY24 Guidance

